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Abstract
Objectives: This study describes changes in the survival of patients with hepatocellular carcinoma
(HCC) registered with the Scottish Cancer Registry between 1985 and 2008.
Methods: Data on patients diagnosed with HCC were extracted from the Scottish Cancer Registry,
along with linked data on treatment and risk factors for liver disease. One-, 3- and 5-year relative survival
rates were calculated for each time period and a Cox regression model was used to assess the impact
of prior admissions on survival.
Results: The incidence of HCC increased between 1985 and 2008. The proportion of patients with prior
alcohol-related admissions rose over the time period studied from 16.0% to 27.1%. Five-year relative
survival increased in women between 1985–1989 and 2005–2007 from 0.5% [95% confidence interval (CI)
0.0–3.7] to 10.6% (95% CI 5.2–18.1). In men, 5-year relative survival increased from 0.4% (95% CI
0.2–2.2) to 4.4% (95% CI 1.5–9.9). Regression analysis showed that older age, history of alcohol-related
admissions and deprivation were associated with lower survival, and hospitalization for viral hepatitis was
associated with higher survival.
Conclusions: Against the background of an increasing incidence of HCC in Scotland, survival times
have increased substantially.
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Introduction
The annual incidence of and mortality associated with primary
hepatic malignancy in the UK has increased over the past two
decades.1,2 This is thought to have resulted largely from increasing
hepatitis C infections and rising rates of harmful alcohol con-
sumption, both of which exist in the context of an increasing
obesity problem.3 Certainly, primary hepatic malignancy is an
increasingly important public health problem and has become
one of the 20 most frequent cancers in the UK and the 10th most
common cause of death by cancer in men in Scotland.1,2 Rising
trends in primary liver cancer are not exclusive to the UK. In the
USA, liver and bile duct cancer rose from 14th place in 1990 to
ninth in 2005 in terms of its contribution to annual cancer-related
deaths.4
Prior analyses have shown that survival in primary liver cancer is
low; 1-year survival in Scotland was 10% between 1985 and 1990.5
Twomajor changes in clinical practicemayhave affected survival in
primary liver cancer over the past two decades: an increasing range
of treatments for unresectable disease, and increased surveillance
for early-stage disease.6 Advances in chemoembolization, ablation
and surgical resection techniques have been shown to improve the
prospects of surviving this disease considerably.7,8 Although cura-
tive rates for these treatments are still low, these procedures have
improved the ability to retain liver tissue and thus function. Fur-
thermore, transplant surgery has advanced significantly and the
identification of those patients most likely to benefit from liver
replacement has resulted in better outcomes.9
This study reviews Scottish cancer registrations of hepatocellu-
lar carcinoma (HCC) linked with hospital admissions and death
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data to determine trends in survival and factors influencing
survival.
Materials and methods
Cases of cancer in Scotland are registered through a comprehen-
sive system that collects data from several sources. These are com-
bined to create a single case registration based on the primary
cancer type. Data are collected from pathology, radiotherapy,
oncology, neuro-oncology and haematology departments.
Further data are collected from the national databases of hospital
admissions, screening programmes, prospective cancer audits and
death registrations. These records are linked by probability match-
ing and merged to create a single record for each cancer diagnosis,
which is linked to hospital admissions. Patients seen in private
care are also registered on this system.
Individuals aged > 20 years who were registered with a diagno-
sis of primary liver cancer between 1 January 1985 and 31 Decem-
ber 2008 were selected. These included all patients coded with
ICD-9 code 155.0, ICD-10 code C22.0 and corresponding mor-
phology codes ICD-O(1–3) 8170–8176.10 Patients with cholangi-
ocarcinoma [ICD-9 155.1, ICD-10 C22.1 and morphology codes
ICD-O(1–3) 8050, 8140–8141, 8160–8161, 8260, 8440, 8480–
8500, 8570–8572] were excluded from the analysis of survival, as
were patients with unknown morphology in view of the high risk
for misclassifying secondary tumours. Patients who were identi-
fied by death certificate only (DCO) were also excluded. Patients
without histological verification were included in the analysis.
Information on tumour morphology, registration type, age at
diagnosis, gender and postcode was extracted from the cancer
registry data. Data on hospital admissions (within the 5 years
prior to diagnosis) for liver cirrhosis, primary biliary cirrhosis,
haematochromatosis, viral hepatitis, diabetes and ischaemic heart
disease were extracted from the electronic database of hospital
admissions (SMR01). Data on diabetes and ischaemic heart
disease were extracted to give a measure of the impact of non-
alcoholic fatty liver disease (NAFLD) on disease risk. Alcohol-
related diseases were selected according to the predefined list of
conditions used by the Information Services Division’s substance
misuse team, which have been published elsewhere.11 The cancer
registry has no information on tumour staging of liver cancers
and thus a proxy for disease severity was devised; patients with an
admission to hospital for metastatic disease (ICD-10 codes C77,
C78, C79 and ICD-9 codes 196, 197, 198) within 4 weeks of
diagnosis were defined as having more severe disease. At present,
no data on primary liver malignancies are collected from screen-
ing or prospective cancer audits by the Scottish Cancer Registry.
Socioeconomic deprivation was measured using the Scottish
Index of Multiple Deprivation, a geographic indicator based on 37
indicators across income, employment, health, education, skills
and training, geographic access, crime and housing.12
The hospital admissions database (SMR01) contained informa-
tion on procedures and operations. These data were extracted to
identify those individuals who had undergone resection or trans-
plantation. The coding was unable to distinguish between patients
treated with ablation and chemoembolization, respectively, and
these were coded into a category referred to as ‘non-resection
treatments’.
The cohort of patients with HCC was divided according to
periods of diagnosis and the proportions of patients with each risk
factor were calculated within these categories.
Age-standardized incidence rates were calculated by sex using
the European standard population. Date and cause of death were
extracted from the linked data on death certifications. Relative
survival rates were calculated for 1 year, 3 years and 5 years for the
population diagnosed between 1985 and 31 December 2007 using
the ‘strel’ program developed by the London School of Hygiene
and Tropical Medicine (LSHTM) for calculating relative survival
with the statistical analysis program stata (StataCorp LP, College
Station, TX, USA).13,14 Relative survival is a measure of survival
based on the ratio of observed to expected survival for that age
group and location. Expected mortality rates are based on actu-
arial life tables compiled by the General Register Office for Scot-
land (now part of National Records of Scotland) and converted
into a stata format by the LSHTM. Right-hand censor date was
limited to the end of 2007 because life tables for the strel program
were not available for the years 2008 and 2009. stata Version 11
was used for all other statistical analyses.
The relationship between risk factors and cancer-specific sur-
vival was calculated using Cox regression for patients diagnosed
between the years 1997 and 2008. These years were selected as data
on treatment were available from 1997, when regional cancer
registries in Scotland were centralized. The proportional hazards
assumption was tested using the sphtest program based on Sch-
oenfield residuals, and violation of the proportional hazards
assumption was assumed at P < 0.05. Survival dates were right-
hand censored at 31 December 2008. Cancer-specific deaths were
those defined as any death by neoplasm (ICD-9 codes 140–239
and ICD-10 codes C00–D48). All deaths by other causes were
treated as right-hand censored at the date of death.
Results
Of the initial dataset of 5846 primary cancers, 264 (4.5%) were
DCO diagnoses and were excluded from analysis. During the
23-year study period, 2802 patients were diagnosed with HCC as
defined by topography and morphology code. The proportion of
histologically verified registrations of HCCwas 80.6%, but this fell
to 42.5% over the study period (Table 1). The remainder of the
registrations referred to cholangiocarcinoma, were of non-specific
morphology or had a mixed topography and morphology (i.e.
topography of biliary cancer with a morphology code for HCC).
The annual age-standardized incidence of HCC increased
between 1985 and 2008 (Fig. 1). In 1997, a temporary rise in
registrations coincided with the centralization of the regional
registries into a single national registry. The rate of increase rose
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Table 1 Risk factors and demographics in patients diagnosed with hepatocellular carcinoma (HCC) in Scotland during 1985–2008 (n = 2802)
1985–1989 1990–1994 1995–1999 2000–2004 2005–2008
HCC diagnoses, n 355 395 562 669 821
Age, years, mean  SD 68.59  11.27 67.63  11.80 67.75  10.92 68.49  10.62 68.37  10.74
Male, n (%) 265 (74.6%) 297 (75.2%) 421 (74.9%) 511 (76.6%) 644 (78.4%)
Deprivation quintile 1a, n (%) 130 (36.6%) 113 (28.6%) 164 (29.2%) 166 (24.9%) 238 (29.0%)
Deprivation quintile 2, n (%) 79 (22.3%) 91 (23.0%) 130 (23.1%) 171 (25.6%) 194 (23.6%)
Deprivation quintile 3, n (%) 57 (16.1%) 76 (19.2%) 104 (18.5%) 132 (19.8%) 151 (18.4%)
Deprivation quintile 4, n (%) 42 (11.8%) 62 (15.7%) 76 (13.5%) 90 (13.5%) 145 (17.7%)
Deprivation quintile 5, n (%) 47 (13.2%) 53 (13.4%) 88 (15.7%) 109 (16.3%) 93 (11.3%)
Metastasesb, n (%) 28 (8.0%) 36 (9.3%) 60 (10.7%) 71 (10.6%) 90 (11.1%)
Viral hepatitis, n (%) 5 (1.4%) 14 (3.6%) 45 (8.0%) 48 (7.2%) 67 (8.2%)
Liver cirrhosis, n (%) 95 (27.1%) 112 (28.9%) 161 (28.8%) 130 (19.4%) 202 (24.8%)
Alcoholic liver cirrhosisc, n (%) 37 (10.5%) 49 (12.6%) 81 (14.5%) 67 (10.0%) 115 (14.1%)
Non-alcoholic liver cirrhosisd, n (%) 58 (16.3% 63 (15.9%) 80 (14.2%) 63 (9.4%) 87 (10.6%)
Biliary cirrhosis, n (%) 8 (2.3%) 14 (3.6%) 18 (3.2%) 22 (3.3%) 27 (3.3%)
Haemochromatosis, n (%) 18 (5.1%) 15 (3.9%) 23 (4.1%) 31 (4.6%) 43 (5.3%)
Alcohol-related admission, n (%) 56 (16.0%) 73 (18.8%) 131 (23.4%) 158 (23.7%) 220 (27.1%)
Diabetes, n (%) 37 (10.5%) 57 (14.7%) 83 (14.8%) 132 (19.7%) 214 (26.3%)
Hypertension, n (%) 12 (3.4%) 21 (5.4%) 49 (8.8%) 92 (13.8%) 189 (23.2%)
Ischaemic heart disease, n (%) 28 (8.0%) 43 (11.1%) 78 (13.9%) 89 (13.3%) 125 (15.4%)
Transplant, n (%) 0 4 (1.0%) 14 (2.5%) 32 (4.8%) 34 (4.1%)
Histological verification, n (%) 286 (80.6%) 304 (77.0%) 378 (67.3%) 376 (56.2%) 349 (42.5%)
aDeprivation quintile 1 represents the most deprived.
bAdmitted with metastases within 4 weeks of diagnosis.
cIndividuals with a diagnosis of liver cirrhosis and an alcohol-related admission.
dIndividuals with a diagnosis of liver cirrhosis and no alcohol-related admission.
SD, standard deviation.
Figure 1 European age-standardized rates of hepatocellular carcinoma (HCC) per 100 000 population in Scotland by year of incidence
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sharply following the year 2000 to the present. This principally
reflected rising numbers of male registrations. The rate of inci-
dence in males was approximately three times greater than that in
women. The relative increase was similar in both groups; however,
males account for an increasing proportion of registrations as a
result of their high baseline rate (Fig. 1).
The mean age at presentation of patients with HCC remained
the same through all five periods observed. The inequalities in
HCC distribution amongst the deprivation quintiles fell across the
time periods observed. The absolute difference between the pro-
portion of registrations from themost and least deprived quintiles
fell from 23.4% to 17.7% through the study period (Table 1).
The proportion of patients with a prior admission of viral
hepatitis rose sharply after 1990, but reached a plateau in the
2000s. The proportion of patients with prior alcohol-related
admissions rose consistently throughout the period under study,
whereas the proportion of patients with a diagnosis of alcoholic
cirrhosis was at its highest in the late 1990s.
The absolute numbers of patients with an admission for
primary biliary cirrhosis (PBC) rose through the 5-year periods,
although this did not result in a large increase in the proportion of
total registrations of HCC with PBC. The frequency of haemo-
chromatosis also rose within the context of a rising incidence of
HCC and thus proportions remained relatively stable (Table 1).
The number of patients with measured comorbidities rose in
each time period. The proportions of patients with diabetes,
hypertension or ischaemic heart disease rose throughout the study
period (Table 1).
Over the period under study, the proportion of patients admit-
ted to hospital with metastases within 4 weeks of diagnosis rose
slightly from 1985–1989 to 2005–2008 (Table 1).
Although incidence increased dramatically during this study
period, there have been a host of innovations in treatment. The
Scottish Liver Transplant Unit was first established in 1992 and
has since undertaken over 1000 successful liver transplants. This is
reflected in the rise in the proportion of patients recorded as
undergoing liver transplantation (Table 1).
Relative survival was calculated using 2590 patients with HCC
diagnosed between 1 January 1985 and 31 December 2007. It was
not possible to calculate age-standardized relative survival as a
result of low sample numbers. Relative survival increased signifi-
cantly during the study period (Table 2). One-year survival
amongmales during 2005–2007 was five times greater than that in
1985–1989. Three-year survival among males also increased sig-
nificantly. Five-year survival in male patients also increased,
although not significantly. Relative 1-, 3- and 5-year survival
among females increased significantly. Cox survival analysis was
performed on the 1836 patients diagnosed between 1997 and the
end of 2008. The model adjusted for all recorded risk factors,
cardiovascular comorbidities and surgical treatments, including
transplant and resection, and a combined variable for extirpation
and ablation, which were inseparable in the coding. Each addi-
tional year of age at diagnosis, the presence of metastatic disease,
and alcohol-related admissions all independently reduced survival
(Table 3).
Relative to patients in the most deprived quintile, being in the
two least deprived quintiles was associated with a significant
improvement in survival. As reflected in the increasing relative
survival seen in Table 2, year of incidence was also significantly
associated with an increase in survival. Finally, patients with an
admission for viral hepatitis had a significantly lower hazard ratio
than those without.
Discussion
This work has confirmed the increase in risk for primary liver
cancer that has occurred in Scotland over the past 25 years, but has
also shown apparent associated improvements in survival. Annual
incidences of HCC have doubled since 1985 in both men and
women, although male incidence rates are several times higher
Table 2 Relative survival (%) at 1, 3 and 5 years in patients diagnosed with hepatocellular carcinoma in Scotland during 1985–2008 (n = 2802)
1-year survival, % (95% CI) 3-year survival, % (95% CI) 5-year survival, % (95% CI)
Women
1985–1989 10.7 (5.6–17.7) 2.4 (0.6–6.9) 0.5 (0.0–3.7)
1990–1994 14.6 (8.6–22.0) 5.4 (2.1–11.0) 5.4 (2.1–11.0)
1995–1999 16.3 (10.8–22.8) 9.7 (5.5–15.4) 7.1 (3.6–12.2)
2000–2004 28.2 (21.3–35.5) 11.6 (7.0–17.5) 8.7 (4.7–14.2)
2005–2007 32.1 (24.1–40.4) 12.6 (7.2–19.6) 10.6 (5.2–18.1)
Men
1985–1989 5.2 (3.1–8.0) 0.7 (0.2–2.2) 0.4 (0.2–2.2)
1990–1994 9.2 (6.5–12.6) 3.2 (1.6–5.7) 2.2 (0.9–4.5)
1995–1999 18.4 (14.9–22.3) 7.9 (5.5–10.8) 5.5 (3.5–8.3)
2000–2004 26.7 (22.9–30.7) 11.0 (8.3–14.1) 8.7 (6.2–11.6)
2005–2007 26.8 (22.8–30.8) 11.8 (8.9–15.2) 4.4 (1.5–9.9)
95% CI, 95% confidence interval.
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than those of females. The rate of 1-year survival in women has
increased three-fold and that in men has increased by over five-
fold since 1985–1989. There has also been an improvement in
5-year survival rates, which have risen from < 1% to 10.6% in
women and 4.4% in men. Risk factors for HCC, such as alcohol-
related admissions, alcohol-related cirrhosis admissions and
viral hepatitis admissions all rose throughout the study period.
However, the presence of a viral hepatitis admission was not asso-
ciated with a reduction in survival. Viral hepatitis admissions,
being in the two least deprived quintiles, and diagnosis in more
recent years were all associated with improved survival.Metastatic
disease, increasing age and prior alcohol-related admissions all
reduced survival.
This study was based on national cancer registry data covering
the whole of Scotland. The Scottish Cancer Registry has high-
quality data capture and coding.15 In the most recent report by the
International Agency for Research on Cancer (IARC), DCO
records for liver cancer were reported to have fallen to < 1%.16
However, falling rates of histological verificationmake the veracity
of case ascertainment increasingly difficult to assess. Nonetheless,
this fall is not unexpected. The dramatic technical advances in
liver transplantation and hepatic resection over the time period
reviewed have led to pressure to change diagnostic standards to
reduce metastatic tumour seeding in patients who undergo cura-
tive surgery. In these cases, the only possibility for a biopsy would
be during surgery or at postmortem. Modern clinical guidelines
indicate that a firm diagnosis can bemade in the absence of biopsy
if satisfactory imaging in two modalities, with or without a raised
serum alpha fetoprotein level, are present. Thus, lesions are not
biopsied initially as patients are considered for surgery and,
although most patients do not fulfil criteria for curative surgery,
their diagnosis is established and there is no requirement for
histological confirmation.17
The combination of morphological and topographical codes
improves the specificity of diagnoses and reduces the likelihood
that misclassified secondary tumours will be inadvertently
included. The cancer registry does not collect detailed clinical
data or measures of severity. A proxy measure of severity was
based on the presence of an admission for metastatic disease
within 4 weeks of diagnosis. This method has effectively
identified patients with poor survival previously.18 It may have
limitations in HCC specifically as this tumour metastasizes
uncommonly and late, and the severity of illness reflects liver
failure rather than tumour bulk. Nevertheless, it was an inde-
pendent predictor of prognosis in the present study.
Rising rates of HCC in the UK have been reported previously.19
In Scotland, the combination of high rates of alcohol abuse in the
general population and high hepatitis C prevalences in the drug-
using population have contributed heavily to the current increase
in liver disease and subsequent development of primary liver can-
cers.20 One in four of those diagnosed with HCC since 2005 had a
prior alcohol-related admission to hospital. However, in recent
years the rise in alcohol-related mortality appears to have reached
a plateau.21 The high prevalence of alcohol misuse may influence
Table 3 Cox regression of risk factors against survival time adjusted for all risk factors and surgical treatment (transplant, resection,
extirpation, ablation) in patients diagnosed with hepatocellular carcinoma in Scotland during 1985–2008 (n = 2802)
Risk factor HR HR (adj) SE P-value 95% CI
Age 1.02 1.01 0.002 0.000c 1.01–1.02
Sexa 1.04 1.03 0.066 0.612 0.91–1.17
Metastases 2.39 1.96 0.156 0.000c 1.67–2.29
Viral hepatitis 0.50 0.71 0.082 0.003c 0.57–0.89
Primary biliary cirrhosis 0.82 0.90 0.133 0.455 0.67–1.20
Haemochromatosis 0.72 0.81 0.107 0.120 0.63–1.05
Diabetes 1.04 0.95 0.064 0.433 0.83–1.08
Ischaemic heart disease 1.17 1.03 0.081 0.742 0.88–1.20
Alcohol-related admission 0.99 1.23 0.102 0.013c 1.05–1.45
Alcoholic cirrhosis 0.90 0.88 0.097 0.263 0.71–1.10
Year of incidence 0.98 0.98 0.008 0.039c 0.97–0.99
Deprivation quintile 1b 1.00
Deprivation quintile 2 0.84 0.91 0.066 0.194 0.79–1.05
Deprivation quintile 3 0.88 0.93 0.073 0.355 0.80–1.08
Deprivation quintile 4 0.72 0.76 0.065 0.001c 0.64–0.90
Deprivation quintile 5 0.75 0.83 0.072 0.030c 0.70–0.98
aFemale baseline.
bDeprivation quintile 1 = most deprived.
cP < 0.05.
HR, hazard ratio; SE, standard error; 95% CI, 95% confidence interval.
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survival in two main ways: it may delay patients from seeking
treatment, or it may encourage poor tolerance of and adherence
to treatment.
Understanding of the relationship between HCC incidence,
viral hepatitis and cirrhosis, along with the development of cura-
tive treatments, has led to a widespread increase in the practice of
screening at-risk patients for early disease. This appears to have
led to improvements in survival which may, in part, reflect ‘lead-
time bias’, but may also result from the greater susceptibility to
intervention of early-stage tumours.6 It should also be noted that
during the past 15 years, the provision of liver transplantation has
expanded rapidly in Scotland.22,23 Newer non-surgical invasive
techniques have been shown to improve short-term survival pros-
pects in early-stage disease. Radiofrequency ablation and percu-
taneous ethanol injection have both been shown to treat patients
with small tumours (< 2 cm in diameter) effectively. However, at
presentation, the majority of patients are found to be unsuitable
for curative treatment because of either tumour size or location,
or underlying liver failure. Therefore, the majority of chemoem-
bolization and ablation procedures are performed with palliative
intent and aminority of patients derive prolonged survival. This is
consistent with the present study’s finding of more striking abso-
lute increases over time in 1-year compared with 5-year survival.
It was not possible to estimate age-adjusted relative survival
from this dataset as even broad age groups were underpowered.
The relative survival analysis allows adjustment for background
mortality. This is important because in Scotland cardiovascular
disease mortality, obesity and alcohol abuse, as well as mortality
from certain cancers, are higher than in most other European
countries.24 Survival measures which do not adjust for this are
likely to underestimate survival as deaths which should be attrib-
uted to other causes are attributed to the cancer of interest.
Viral hepatitis is recorded in this dataset as an admission to
hospital with viral hepatitis. This is more likely in patients with
more severe disease and the dataset does not represent a compre-
hensive record of all patients with hepatitis C or B in Scotland.
However, the obvious increase in patients with a diagnosis of viral
hepatitis across time periods reflects the increase in testing for
hepatitis C that has occurred since the early 1990s.
In conclusion, rates of HCC are increasing in Scotland, most
likely as a result of increasing levels of alcohol abuse in the general
population and viral hepatitis among i.v. drug users. Despite this,
there is hope for survival that was not possible 25 years ago.
Survival has risen significantly, no doubt partly as a result of the
earlier diagnosis facilitated by improved surveillance, but also
potentially as a result of the increased availability of several novel
treatments and interventions, including aggressive surgical resec-
tion, ablation and transplantation. Further research correcting for
severity at presentation will be required to quantify the impacts of
surveillance and treatment, respectively, on changing rates of
survival. Given the current plateau in alcohol-related mortality
in Scotland, this burden of liver cancer may even decline in the
medium term if current initiatives set to reduce the burden of
alcohol-related harm continue to be supported and new initiatives
are put in place.
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